BMI in Idiopathic Intracranial Hypertension and Its Relationship With the Response to Treatment
Recruiting · NCT06913712 · Observational (researchers observe without assigning treatment) · Lead sponsor: University of Valencia
View the official record on ClinicalTrials.gov →Interventions studied
Weight loss without pharmacotherapy
What this trial is about
1. To establish the correlation between the evolution of the body mass index in benign intracranial hypertension and the response to treatments. 2. To establish the BMI at which this disease occurs. 3. To establish how much the BMI must be reduced to cure this disease. 4. To assess the evolution and response to treatments of sick people who DO NOT reduce or even continue to increase their BMI despite treatment with Acetazolamide or a possible CSF diversion
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Adults aged 18 years and older at the time of enrollment. There is no upper age limit to ensure inclusivity across age ranges.
- A confirmed diagnosis of Idiopathic Intracranial Hypertension, established according to the Dandy criteria.
- The diagnostic process must exclude other potential causes of increased intracranial pressure as detailed in the 'Diagnosis' section, ensuring an accurate identification of idiopathic cases.
Exclusion criteria
- A diagnosis other than IIH, specifically: tension-type headache, Chiari I malformation, or any other headache disorder unrelated to IIH.
- The presence of secondary causes of increased intracranial pressure (e.g., structural brain abnormalities, venous sinus thrombosis, or medication-induced factors).
Where it is running
1 location listed.
- Consorcio Hospital General Universitario de Valencia - Valencia, Valencia, Spain